Semaglutide Therapy for Alcohol Reduction - Tulsa

Part of paid clinical trials in Tulsa, Oklahoma.

Sponsor
Oklahoma State University Center for Health Sciences
Study ID
NCT05891587
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Semaglutide pen injector
  • Placebo — DRUG
    Saline solution

Study Details

The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.

Key Dates

Start date
Jul 7, 2023
Status verified
Dec 2025
Primary completion
Jul 30, 2025
Completion
Oct 1, 2025

Study Design

Enrollment
80 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Participants will receive subcutaneous injections of semaglutide in escalating doses (.25mg to 1.0mg) over the course of 12 weeks.
  • Placebo Comparator: Placebo
    Participants will receive subcutaneous injections of a placebo saline solution over the course of 12 weeks.

Primary Outcome Measure

Change in alcohol drinks per drinking day. [ Time Frame: Baseline (Week 1) to post-medication (Week 13) ]

Locations (1)

FacilityCityStateZIPSite coordinators
OSU Biomedical Imaging CenterTulsaOklahoma74136-

Find similar trials in Tulsa, OK

By condition
Substance use disorder
By specialty
Behavioral healthAddiction medicine
By research site
OSU Biomedical Imaging Center· Tulsa, OK

Related Studies